# Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis

> **NCT05410470** · — · COMPLETED · sponsor: **Qilu Hospital of Shandong University** · enrollment: 130 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05410470
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2022-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410470, "Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05410470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*